Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Anvs save search
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 10.43%
H: 34.62%
C: 12.69%
announcement disease alzheimer’s update buntanetap study
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: 2024-02-14 (Crawled : 13:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 2.99%
H: 2.51%
C: 0.19%
disease alzheimer’s buntanetap study
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Published: 2023-12-05 (Crawled : 12:30) - globenewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 1.52%
H: 11.4%
C: 3.0%
disease buntanetap parkinson’s study
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 4.62%
H: 17.65%
C: 8.68%
disease alzheimer’s
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
Published: 2023-10-30 (Crawled : 23:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: -0.12%
H: 3.62%
C: 1.88%
disease alzheimer’s positive buntanetap trial
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
Published: 2023-10-24 (Crawled : 00:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 0.76%
H: 7.38%
C: -1.0%
drug conference disease trials alzheimer's
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
Published: 2023-06-20 (Crawled : 21:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: -0.97%
H: 9.35%
C: 6.25%
disease positive buntanetap parkinson’s trial
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
Published: 2023-06-08 (Crawled : 13:20) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 8.73%
H: 0.0%
C: -9.01%
disease parkinson's treatment
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
Published: 2023-04-27 (Crawled : 11:00) - globenewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 2.36%
H: 1.52%
C: -1.18%
drug patent disease treatment
ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
Published: 2023-04-13 (Crawled : 12:00) - prnewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 3.01%
H: 10.05%
C: 5.23%
disease parkinson's review alzheimer's
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Published: 2023-02-08 (Crawled : 13:00) - prnewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 3.07%
H: 2.67%
C: -1.85%
treatment disease parkinson's buntanetap trial approval study
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
Published: 2023-01-25 (Crawled : 13:00) - prnewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 6.62%
H: 0.0%
C: -5.09%
treatment disease parkinson's buntanetap update study
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
Published: 2022-10-11 (Crawled : 12:00) - prnewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: -0.4%
H: 2.96%
C: 0.96%
disease alzheimer's publication phase 2b
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 9.5%
H: 0.61%
C: -6.49%
fda disease alzheimer's buntanetap trial authorization phase 2
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
Published: 2022-09-13 (Crawled : 12:00) - prnewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: -7.57%
H: 20.09%
C: 11.9%
treatment disease publication huntington’s disease
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
Published: 2022-08-24 (Crawled : 12:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 6.72%
H: 2.45%
C: -0.79%
disease parkinson's trial
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 11.24%
H: 7.12%
C: 1.69%
fda disease trial positive buntanetap anvs401 posiphen phase 3
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Published: 2022-04-11 (Crawled : 23:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 0.33%
H: 0.16%
C: -4.18%
day disease
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Published: 2022-03-08 (Crawled : 17:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 1.35%
H: 12.25%
C: 4.17%
alzheimer parkinson conference presentation disease alzheimer’s alzheimer's
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Published: 2022-01-25 (Crawled : 17:00) - biospace.com/
ANVS | $11.88 3.39% 0.17% 220K
|
Health Technology
|
| O: 2.75%
H: 5.63%
C: -1.27%
fda parkinson disease positive phase 3 buntanetap
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
VLCN | $0.2946 26.38% 20.17% 15M
|
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
TOVX | News | $0.3769 -8.3% 7.46% 1.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.